Cantor Fitzgerald Reiterates Neutral on Reata Pharmaceuticals, Maintains $172 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Charles Duncan has reiterated a Neutral rating on Reata Pharmaceuticals (NASDAQ:RETA) and maintained a price target of $172.
August 15, 2023 | 2:26 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Reata Pharmaceuticals has received a Neutral rating from Cantor Fitzgerald, with a maintained price target of $172.
The reiteration of a Neutral rating by Cantor Fitzgerald indicates that the analyst sees neither a strong upside nor downside for the stock in the near term. The maintained price target of $172 suggests that the analyst believes the stock is fairly valued at this price. This could lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100